PHILADELPHIA, March 25, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Paragon 28, Inc. (“Paragon”) (NYSE: FNA) shareholders. Click here for additional information: https://kaskelalaw.com/case/paragon-28/ On January 28, 2025, Paragon announced that it had agreed to be acquired by Zimmer Biomet Holdings, Inc. (“Zimmer”) at an upfront price of $13.00 per share in cash plus a non-tradable contingent value right (CVR) worth up to an additional $1.00 in cash upon the achievement of certain milestones. Following the closing of the proposed transaction, Paragon’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded. The investigation seeks to determine whether Paragon’s shareholders will be receiving sufficient monetary consideration for their shares, and whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to the buyout price with Zimmer. Notably, at the time the proposed transaction was announced, several stock analysts were maintaining price targets for the company’s shares at or above $15.00 per share. Paragonshareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser): https://kaskelalaw.com/case/paragon-28/ Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis, which means that the firm’s clients never pay any out-of-pocket costs for legal representation. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com. CONTACT: KASKELA LAW LLC D. Seamus Kaskela, Esq. ([email protected]) Adrienne Bell, Esq. ([email protected]) 18 Campus Blvd., Suite 100 Newtown Square, PA 19073 (484) 229 – 0750 www.kaskelalaw.com This notice may constitute attorney advertising in certain jurisdictions.
PARAGON 28 STOCKHOLDER NOTICE: Kaskela Law LLC Announces Investigation of Paragon 28, Inc. (NYSE: FNA) Proposed Stockholder Buyout and Encourages Investors to Contact the Firm for Additional Information
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...